{"nctId":"NCT00281320","briefTitle":"Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)","startDateStruct":{"date":"2006-02"},"conditions":["Psychosis"],"count":122,"armGroups":[{"label":"Asenapine 2-10 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Asenapine"]},{"label":"Asenapine 5-10mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Asenapine"]}],"interventions":[{"name":"Asenapine","otherNames":["Saphris"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Elderly subjects with psychosis\n\nExclusion Criteria:\n\n* Have an uncontrolled, unstable clinically significant\n\nmedical condition.\n\n* Have an established diagnosis of dementia","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Experienced an Adverse Event","description":"Participants who experienced treatment-emergent adverse events, defined as newly reported events after baseline or events reported to have worsened in severity since baseline (from the date of informed consent to the last dose day + 7 days for non-serious adverse events and 30 days for serious adverse events).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Discontinued Because of an Adverse Event","description":"Discontinuations due to treatment-emergent adverse events starting on or after Day1 and up to 7 days after study medication stop date (30 days for serious adverse events).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"PRIMARY","title":"Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis, Tmax","description":"Tmax defined as time to peak concentration.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.06","spread":null}]}]}]},{"type":"PRIMARY","title":"Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis,Cmax","description":"Cmax defined as peak concentration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.01","spread":"3.89"},{"groupId":"OG001","value":"10.3","spread":"6.71"}]}]}]},{"type":"PRIMARY","title":"Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis , Dn-Cmax","description":"dn-Cmax is defined as dose normalized peak concentration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"0.778"},{"groupId":"OG001","value":"1.03","spread":"0.671"}]}]}]},{"type":"PRIMARY","title":"Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis, Cmin","description":"Cmin defined as pre-dose concentration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":"1.87"},{"groupId":"OG001","value":"4.06","spread":"2.70"}]}]}]},{"type":"PRIMARY","title":"Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis, AUC 0-12","description":"AUC 0-12 defined as area-under-the-curve from zero to time point 12 hours.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":"21.1"},{"groupId":"OG001","value":"70.3","spread":"41.8"}]}]}]},{"type":"PRIMARY","title":"Pharmacokinetics of Asenapine up to Doses of 10 mg BID in Elderly Subjects With Psychosis, Dn-AUC 0-12","description":"dn-AUC 0-12 defined as dose-normalized area-under-the-curve from zero to time point 12 hours.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.72","spread":"4.22"},{"groupId":"OG001","value":"7.03","spread":"4.18"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":61},"commonTop":["Hypertension","Headache","Somnolence","Asthenia","Dizziness"]}}}